Company news

Anixa Biosciences, Inc. news in 2026

Anixa Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

November 4, 2026

Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

October 26, 2026

Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine

October 13, 2026

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

October 13, 2026

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

October 5, 2026

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

October 1, 2026

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

September 21, 2026

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

September 16, 2026

Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

September 9, 2026

Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026

September 3, 2026

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

August 24, 2026

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

August 18, 2026

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

July 14, 2026

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

July 6, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

June 29, 2026

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

June 26, 2026

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

June 11, 2026

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

May 31, 2026

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

May 11, 2026

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

May 1, 2026

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

April 29, 2026

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell and Gene Therapy 2026 Annual Meeting

April 23, 2026

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

April 22, 2026

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

April 9, 2026

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

April 6, 2026

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

April 5, 2026

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

March 31, 2026

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

March 29, 2026

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

March 11, 2026

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

March 8, 2026

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

March 2, 2026

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

February 23, 2026

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

February 9, 2026

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

February 2, 2026

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

January 27, 2026

Annual Report for Fiscal Year Ending October 31, 2025 (Form 10-K)

January 12, 2026

Decks in 2026